Therefore, the PI3K/Akt/mTOR pathway serves as a crucial regulator of eosinophil survival, activation, and degranulation, making it a potential therapeutic target for controlling eosinophil function and ECP release to thereby reduce tissue damage and alleviate the symptoms of inflammatory and allergic diseases. This evidence concerns the gene MTOR and allergic disease.